MEDINCELL SA (MEDCL.PA) Fundamental Analysis & Valuation

EPA:MEDCL • FR0004065605

Current stock price

24.65 EUR
-0.17 (-0.68%)
Last:

This MEDCL.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MEDCL.PA Profitability Analysis

1.1 Basic Checks

  • MEDCL had negative earnings in the past year.
  • MEDCL had a negative operating cash flow in the past year.
  • In the past 5 years MEDCL always reported negative net income.
  • MEDCL had negative operating cash flow in 4 of the past 5 years.
MEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFMEDCL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M -20M -30M

1.2 Ratios

  • The Return On Assets of MEDCL (-26.75%) is worse than 75.51% of its industry peers.
Industry RankSector Rank
ROA -26.75%
ROE N/A
ROIC N/A
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MEDCL.PA Yearly ROA, ROE, ROICMEDCL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • With an excellent Gross Margin value of 85.42%, MEDCL belongs to the best of the industry, outperforming 91.84% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MEDCL has grown nicely.
  • MEDCL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
MEDCL.PA Yearly Profit, Operating, Gross MarginsMEDCL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MEDCL.PA Health Analysis

2.1 Basic Checks

  • MEDCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MEDCL has more shares outstanding
  • Compared to 5 years ago, MEDCL has more shares outstanding
  • MEDCL has a better debt/assets ratio than last year.
MEDCL.PA Yearly Shares OutstandingMEDCL.PA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MEDCL.PA Yearly Total Debt VS Total AssetsMEDCL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • MEDCL has an Altman-Z score of 5.09. This indicates that MEDCL is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 5.09, MEDCL is doing good in the industry, outperforming 75.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 5.09
ROIC/WACCN/A
WACC7.67%
MEDCL.PA Yearly LT Debt VS Equity VS FCFMEDCL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

  • MEDCL has a Current Ratio of 2.88. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
  • MEDCL has a better Current ratio (2.88) than 87.76% of its industry peers.
  • MEDCL has a Quick Ratio of 2.88. This indicates that MEDCL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.88, MEDCL belongs to the top of the industry, outperforming 91.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.88
Quick Ratio 2.88
MEDCL.PA Yearly Current Assets VS Current LiabilitesMEDCL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. MEDCL.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 43.15% over the past year.
  • The Revenue has grown by 166.31% in the past year. This is a very strong growth!
  • Measured over the past years, MEDCL shows a very strong growth in Revenue. The Revenue has been growing by 54.88% on average per year.
EPS 1Y (TTM)43.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.92%
Revenue 1Y (TTM)166.31%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%34.66%

3.2 Future

  • The Earnings Per Share is expected to grow by 38.42% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 33.30% on average over the next years. This is a very strong growth
EPS Next Y56.37%
EPS Next 2Y62.14%
EPS Next 3Y54.58%
EPS Next 5Y38.42%
Revenue Next Year5.64%
Revenue Next 2Y47.92%
Revenue Next 3Y65.97%
Revenue Next 5Y33.3%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
MEDCL.PA Yearly Revenue VS EstimatesMEDCL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
MEDCL.PA Yearly EPS VS EstimatesMEDCL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

2

4. MEDCL.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MEDCL. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 51.28 indicates a quite expensive valuation of MEDCL.
  • Based on the Price/Forward Earnings ratio, MEDCL is valued a bit more expensive than the industry average as 65.31% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.68, MEDCL is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 51.28
MEDCL.PA Price Earnings VS Forward Price EarningsMEDCL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEDCL.PA Per share dataMEDCL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as MEDCL's earnings are expected to grow with 54.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.14%
EPS Next 3Y54.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MEDCL.PA Dividend Analysis

5.1 Amount

  • No dividends for MEDCL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDCL.PA Fundamentals: All Metrics, Ratios and Statistics

MEDINCELL SA

EPA:MEDCL (4/30/2026, 5:29:47 PM)

24.65

-0.17 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength53.38
Industry Growth58.67
Earnings (Last)12-09
Earnings (Next)06-16
Inst Owners31.1%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap885.18M
Revenue(TTM)28.41M
Net Income(TTM)-19.95M
Analysts85.88
Price Target34.69 (40.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.54%
PT rev (3m)-3.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-14.6%
EPS NY rev (3m)-8.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.4%
Revenue NY rev (3m)-6.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 51.28
P/S 31.16
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.48
Fwd EY1.95%
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.79
BVpS-0.85
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -26.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 85.42%
FCFM N/A
ROA(3y)-65.75%
ROA(5y)-56.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.72%
GM growth 5Y7.65%
F-Score5
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.28%
Cap/Sales 7.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.88
Quick Ratio 2.88
Altman-Z 5.09
F-Score5
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)71.46%
Cap/Depr(5y)81.14%
Cap/Sales(3y)10.03%
Cap/Sales(5y)17.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.92%
EPS Next Y56.37%
EPS Next 2Y62.14%
EPS Next 3Y54.58%
EPS Next 5Y38.42%
Revenue 1Y (TTM)166.31%
Revenue growth 3Y83.86%
Revenue growth 5Y54.88%
Sales Q2Q%34.66%
Revenue Next Year5.64%
Revenue Next 2Y47.92%
Revenue Next 3Y65.97%
Revenue Next 5Y33.3%
EBIT growth 1Y49.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.23%
EBIT Next 3Y97.59%
EBIT Next 5Y75.92%
FCF growth 1Y21.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.67%
OCF growth 3YN/A
OCF growth 5YN/A

MEDINCELL SA / MEDCL.PA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDINCELL SA (MEDCL.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MEDCL.PA.


Can you provide the valuation status for MEDINCELL SA?

ChartMill assigns a valuation rating of 2 / 10 to MEDINCELL SA (MEDCL.PA). This can be considered as Overvalued.


How profitable is MEDINCELL SA (MEDCL.PA) stock?

MEDINCELL SA (MEDCL.PA) has a profitability rating of 1 / 10.